UCB Aktie
| 219,40EUR | -0,80EUR | -0,36% | 
WKN: 852738 / ISIN: BE0003739530
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 8 371 | 8 561 | 8 703 | 9 083 | 9 378 | 
| Umsatz pro Mitarbeiter in Mio. EUR | 0,64 | 0,67 | 0,63 | 0,58 | 0,66 | 
Bilanz (in Mio. EUR) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 3 582 | 3 710 | 3 304 | 3 444 | 4 788 | 
| Summe Anlagevermögen | 9 737 | 10 500 | 12 564 | 12 095 | 12 559 | 
| Summe Aktiva | 13 319 | 14 210 | 15 868 | 15 539 | 17 347 | 
Bilanz (in Mio. EUR) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 6 047 | 5 824 | 6 804 | 6 564 | 7 318 | 
| Summe Eigenkapital | 7 272 | 8 386 | 9 064 | 8 975 | 10 029 | 
| Summe Passiva | 13 319 | 14 210 | 15 868 | 15 539 | 17 347 | 
Adresse
| Allée de la Recherche, 60, 1070 Brussels | |
| Telefon | +32 (2) 559-99-99 | 
| Internet | http://www.ucb.com | 
Management
| 
						Alistair Henry
						 Chief Scientific Officer & Executive VP  | 
				
| 
						Antje Witte
						 Head-Investor Relations  | 
				
| 
						Caroline Vancoillie
						 Head-Group Finance  | 
				
| 
						Charles-Antoine Janssen
						 Vice Chairman  | 
				
| 
						Cyril Janssen
						 Director  | 
				
| 
						Dame Kay Davies
						 Independent Director  | 
				
| 
						Denelle J. Waynick
						 Executive Vice President & General Counsel  | 
				
| 
						Dolca Thomas
						 Independent Director  | 
				
| 
						Dominique Baeten
						 Head-New Patient Value Mission  | 
				
| 
						Emmanuel Caeymaex
						 Chief Commercial Officer & Executive VP  | 
				
| 
						Jan Berger
						 Independent Director  | 
				
| 
						Jean Luc Fleurial
						 Chief Human Resources Officer & Executive VP  | 
				
| 
						Jean-Christophe Tellier
						 Chief Executive Officer & Executive Director  | 
				
| 
						Jonathan M. Peacock
						 Chairman  | 
				
| 
						Jonkheer Cédric van Rijckevorsel
						 Director  | 
				
| 
						Kirsten Lund Jurgensen
						 Executive Vice President-Patient Supply  | 
				
| 
						Maëlys Castella
						 Independent Director  | 
				
| 
						Nefertiti Greene
						 Independent Director  | 
				
| 
						Pierre L. Gurdjian
						 Independent Director  | 
				
| 
						Raf Remijsen
						 Head-Treasury & Risk Management  | 
				
| 
						Rodolfo J. Savitzky
						 Independent Director  | 
				
| 
						Sandrine Dufour
						 Chief Financial Officer & Executive Vice President  | 
				
| 
						Susan Gasser
						 Independent Director  | 
				
| 
						Thomas Debeys
						 Head-Internal Audit  | 
				
| 
						Ulf Arne Wiinberg
						 Independent Director  | 
				
| 
						Xavier Michel
						 Group Secretary General  |